Specifically, methylation at PD-L1 lysine 162 (K162) acts as a negative predictive biomarker for anti–PD-1 treatment in patients with NSCLC and the PD-L1 K162 methylation: PD-L1 ratio provides an even more accurate predictor of therapeutic response [104]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.